Growth Metrics

Amphastar Pharmaceuticals (AMPH) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Q3 2017 value amounting to $1.2 million.

  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue rose 62321.43% to $1.2 million in Q3 2017 from the same period last year, while for Sep 2017 it was $1.2 million, marking a year-over-year increase of 62321.43%. This contributed to the annual value of $97000.0 for FY2016, which is 9275.58% down from last year.
  • Amphastar Pharmaceuticals' Non-Current Deffered Revenue amounted to $1.2 million in Q3 2017, which was up 62321.43% from $423000.0 recorded in Q2 2017.
  • In the past 5 years, Amphastar Pharmaceuticals' Non-Current Deffered Revenue registered a high of $2.6 million during Q4 2013, and its lowest value of $97000.0 during Q4 2016.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Non-Current Deffered Revenue value was $1.3 million (recorded in 2015), while the average stood at $1.3 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Non-Current Deffered Revenue plummeted by 9275.58% in 2016, and later surged by 62321.43% in 2017.
  • Quarter analysis of 5 years shows Amphastar Pharmaceuticals' Non-Current Deffered Revenue stood at $2.6 million in 2013, then fell by 24.5% to $2.0 million in 2014, then crashed by 32.44% to $1.3 million in 2015, then tumbled by 92.76% to $97000.0 in 2016, then skyrocketed by 1152.58% to $1.2 million in 2017.
  • Its Non-Current Deffered Revenue was $1.2 million in Q3 2017, compared to $423000.0 in Q2 2017 and $280000.0 in Q1 2017.